LONDON & NEW YORK – In a significant advancement for cancer research and our understanding of the complex interplay between ageing and disease, a collaborative international team of scientists has unveiled a startling connection between age-related genetic changes in blood cells and aggressive cancer outcomes. Researchers from the Francis Crick Institute, University College London (UCL), Gustave Roussy in France, and the Memorial Sloan Kettering Cancer Center (MSK) in the United States have discovered that the expansion of mutant blood cells, a phenomenon intrinsically linked to ageing, is frequently found within cancerous tumours. This infiltration, termed "tumour infiltrating clonal haematopoiesis" (TI-CH), has been definitively associated with a significantly worse prognosis for patients, regardless of their age or the stage of their cancer diagnosis.
Published today in the prestigious New England Journal of Medicine, this comprehensive study sheds new light on how the natural process of ageing can inadvertently fuel cancer progression. The findings underscore the critical need to understand the biological interface of age-related genetic changes and diseases of ageing, such as cancer and cardiovascular disease, paving the way for the development of innovative preventative and therapeutic strategies for an increasingly ageing global population.
The Unseen Threat of Ageing Blood: Unpacking the Discovery
At the heart of this pivotal research lies an understanding of a condition known as Clonal Haematopoiesis of Indeterminate Potential (CHIP). CHIP is a common, age-related phenomenon where blood stem cells accumulate specific mutations over time. These mutations are influenced by a combination of the ageing process itself and external environmental factors. While CHIP has previously been identified as a risk factor for various age-related disorders, most notably cardiovascular disease, its direct impact on the evolution and aggressiveness of solid cancers had remained largely unexplored until now.
This groundbreaking study bridges that knowledge gap, revealing that these age-acquired mutations are not merely confined to the bloodstream but can actively participate in the hostile environment of a tumour, fundamentally altering its trajectory and, crucially, a patient’s survival prospects. The researchers’ meticulous work across vast patient cohorts has established TI-CH as an independent and powerful predictor of cancer relapse and mortality, marking a new frontier in personalized oncology and age-related disease management.
A Journey of Discovery: Tracing the Link Between CHIP and Cancer
The scientific journey that led to this significant revelation was a multi-faceted and extensive endeavour, spanning several years and involving the analysis of tens of thousands of patient samples.
The Initial Hypothesis and Patient Cohorts:
The impetus for the research stemmed from a growing recognition of the interconnectedness of ageing and disease. Scientists understood that age-related genetic changes, while seemingly benign in many contexts, could hold profound implications for the development and progression of chronic conditions like cancer. To investigate this, the team embarked on a detailed study of the link between CHIP and cancer, leveraging two major Cancer Research UK-funded studies: TRACERx (Tracking Cancer Evolution through therapy (Rx)) and PEACE (Postmortem tissue for studying advanced cancer), which together involved over 400 patients with lung cancer. To validate and expand their findings, they also collaborated with Memorial Sloan Kettering Cancer Center, incorporating data from an immense cohort of 49,000 patients with various types of cancer. This multi-institutional, multi-cohort approach provided an unprecedented scale and depth to the investigation.
Uncovering the CHIP-Prognosis Link:
The first critical step involved an initial examination of blood samples from the lung cancer patients. Using advanced genomic sequencing techniques, the research team was able to accurately determine which patients harboured CHIP mutations in their blood. When this genetic information was meticulously matched with detailed clinical data, a striking pattern emerged. The presence of CHIP mutations in a patient’s blood was consistently associated with a shorter overall survival period. Crucially, this association held true regardless of other significant prognostic factors, such as the patient’s age at diagnosis or the stage at which their cancer was identified, highlighting CHIP as an independent risk factor.
The Emergence of TI-CH: A Deeper Infiltration:
While the initial finding was significant, the researchers sought to understand the precise mechanism behind CHIP’s impact. Their next, and arguably most pivotal, step was to investigate whether these CHIP mutations were not merely circulating in the blood but were actively infiltrating the solid tumours themselves. This required a more detailed analysis of tumour tissue samples from patients already identified with CHIP. The findings were remarkable: in 42% of patients with CHIP, the same mutations were found within their lung tumours, due to the infiltration of mutant blood cells. The team coined a new term for this phenomenon: tumour infiltrating clonal haematopoiesis (TI-CH).
The distinction between CHIP (mutations in blood) and TI-CH (mutations within the tumour) proved to be critical. Further analysis revealed that it was TI-CH, not CHIP alone, that was robustly associated with the greater risk of cancer relapse and, ultimately, cancer-related death. This indicated that the physical presence and interaction of these mutant blood cells within the tumour microenvironment were key drivers of aggressive disease.
Validation in Metastatic Disease:
To reinforce these findings, the team turned to samples from the PEACE study. The PEACE study is a unique postmortem investigation designed to examine areas where cancer has spread (metastatic sites), which are the primary cause of cancer death. The analysis of these metastatic tumours provided compelling corroboration: metastatic sites frequently contained TI-CH mutations, further solidifying the link between these infiltrating mutant blood cells and the most aggressive forms of cancer. This finding underscored that TI-CH was not merely a bystander phenomenon but an active participant in the deadly spread of cancer.
Not All Mutations Are Equal: The Role of Myeloid Cells and TET2
Having established the critical role of TI-CH, the research pivoted towards understanding the biological mechanisms by which these infiltrating cells exert their detrimental effects on tumour progression.
The Myeloid Cell Connection:
To inspect the link between TI-CH and poor patient outcomes, the scientists delved into the cellular composition of the lung tumours. Their investigations revealed that patients with TI-CH exhibited an expansion of myeloid cells, a specific type of immune cell, within their tumours. This was a crucial discovery because myeloid cells are known components of the tumour microenvironment. Unlike some immune cells, such as T-cells, which are primed to recognise and fight cancer, myeloid cells have a more complex and often paradoxical role. While essential for regulating inflammation and tissue repair, they have also been shown to actively support tumour progression, promote angiogenesis (new blood vessel formation), and suppress anti-tumour immune responses, effectively aiding the cancer’s survival and spread. The expansion of these pro-tumourigenic myeloid cells provided a plausible mechanism for TI-CH’s negative impact.
The Significance of TET2 Mutations:
The researchers then focused on identifying specific mutations that might be driving this phenomenon. They discovered that when mutations affected a particular gene called TET2, an important regulator of blood cell production, these TET2 mutant blood cells were significantly more likely to infiltrate the tumour. This observation was made across thousands of individuals. To confirm this at a higher resolution, the team performed single-cell analysis on hundreds of individual cells isolated from the tumours of two patients with TI-CH. This detailed examination confirmed that TET2 mutations were predominantly present in myeloid cells but conspicuously absent in other immune cell types within the tumour, firmly linking TET2 mutations to the myeloid cell expansion observed in TI-CH.
Experimental Validation: Organoids Reveal Causal Link:
To move beyond correlation and establish a causal link, the team collaborated with blood cancer and CHIP experts in a Crick lab led by Dominique Bonnet. In a series of elegant experimental studies, they grew "organoids" – miniature lung tumours – in the presence of TET2 mutant myeloid cells. The results were compelling: the TET2 mutant myeloid cells actively remodelled the tumour microenvironment, creating conditions more favourable for cancer growth, and significantly accelerated the growth of the tumour organoids. This direct experimental evidence provided strong support for the hypothesis that TET2-mutated myeloid cells, characteristic of TI-CH, functionally contribute to aggressive tumour behaviour.
Beyond Lung Cancer: A Universal Predictor Across Cancers
To ascertain the broader applicability of their findings, the research team collaborated with scientists at Memorial Sloan Kettering Cancer Center in the US. This crucial step involved validating their findings using a much larger and more diverse dataset comprising over 49,000 patients with various types of cancer.
The results from this extensive validation cohort were unequivocal: the presence of TI-CH emerged as an independent predictor of shorter survival across this wide spectrum of cancers. While the prevalence of CHIP and TI-CH varied between different cancer types, the negative prognostic impact remained consistent. Notably, researchers found these mutations to be more common in cancers known to be particularly aggressive and harder to treat, such as lung cancer (the initial focus), head and neck cancer, and pancreatic cancer. This broader validation underscores that TI-CH is not a phenomenon unique to lung cancer but represents a fundamental mechanism by which age-related blood cell changes can influence cancer outcomes across a diverse range of malignancies.
Official Responses: Experts Weigh In
The publication of these findings has generated considerable excitement within the scientific and medical communities, with lead researchers highlighting the profound implications of their work.
Dr. Oriol Pich, Postdoctoral Project Research Scientist in the Crick’s Cancer Evolution and Genome Instability Laboratory and a lead author on the study, emphasized the practical significance of the discovery: "Our results show that blood cells carrying age-related mutations can infiltrate tumours and impact cancer evolution, leading to worse outcomes for patients. This is important because CHIP is a natural phenomenon of ageing that is common in patients with cancer. This provides us with a new avenue to understand why some cancers are more aggressive and to explore potential interventions."
Professor Charlie Swanton, Deputy Clinical Director at the Crick, Chief Clinician at Cancer Research UK, and Chief Investigator for TRACERx, spoke to the novelty and future potential of the research: "This is the first time that we’ve been able to see at scale, the interaction of two different types of ‘clonal proliferations’ – age-related CHIP and cancer – providing crucial insight into how ageing might impact cancer risk and progression. As we start to piece together the picture of the most important mutations which evolve during the ageing process in cells from the bone marrow, and the impact they have in disease, we hope we can start to identify opportunities for intervention and maybe even prevention of some age-related cancers. This work truly represents a paradigm shift in our understanding of cancer biology."
The research was generously supported by significant funding from Cancer Research UK and the National Institute of Health and Care Research UCLH Biomedical Research Centre, alongside additional funders, underscoring the collaborative nature and broad importance of this scientific endeavour.
Implications: Reshaping Cancer Diagnostics, Therapies, and Prevention
The discovery of TI-CH and its profound impact on cancer prognosis opens up a plethora of exciting and transformative implications for the future of oncology.
New Diagnostic and Prognostic Markers:
The identification of TI-CH as an independent predictor of shorter survival suggests its potential as a powerful new diagnostic and prognostic marker. Simple blood tests to detect CHIP, followed by more targeted investigations for TI-CH in tumour biopsies, could allow clinicians to stratify patients more accurately according to their risk of relapse and mortality. This could lead to more personalized treatment plans, ensuring that high-risk patients receive more aggressive or novel therapies from the outset, while potentially sparing lower-risk patients from unnecessary intensive treatments. Early detection of CHIP in cancer patients could prompt closer monitoring and proactive management strategies.
Novel Therapeutic Avenues:
Perhaps one of the most exciting implications lies in the potential for developing entirely new therapeutic strategies. By understanding that TET2-mutated myeloid cells contribute to tumour progression, researchers can now explore targeted interventions. This could involve:
- Targeting Myeloid Cell Function: Developing drugs that modulate the pro-tumourigenic activity of myeloid cells within the tumour microenvironment, potentially re-educating them to become anti-tumourigenic or inhibiting their supportive roles.
- Inhibiting TET2 Mutant Cell Expansion: Investigating therapies that specifically target and eliminate or suppress the expansion of TET2-mutated blood stem cells, thereby reducing the pool of cells available to infiltrate tumours.
- Modulating Inflammation: Since myeloid cells regulate inflammation, therapies aimed at dampening inflammation pathways driven by TI-CH could also be explored to impede tumour growth and metastasis.
Understanding the Age-Cancer Axis:
This research significantly advances the field of onco-geriatrics, the study of cancer in older adults. It provides a concrete biological mechanism explaining why older individuals often face more aggressive cancers and poorer outcomes. By dissecting the intricate molecular dialogue between ageing blood cells and the tumour, scientists can gain deeper insights into the fundamental processes that govern age-related disease susceptibility.
The Promise of Prevention:
Looking further into the future, the ultimate goal could be the prevention of certain age-related cancers. If CHIP is a precursor to TI-CH and aggressive disease, then interventions aimed at preventing CHIP, or mitigating its progression, could significantly reduce the incidence and severity of cancer in an ageing population. This could involve lifestyle modifications, pharmacological interventions, or even early gene editing technologies aimed at correcting detrimental mutations in blood stem cells before they lead to disease. While still a distant prospect, the current findings lay a crucial foundation for such ambitious preventative strategies.
Future Research Directions:
The next steps for this transformative work will involve confirming that CHIP directly contributes to cancer outcomes through meticulously designed functional studies. Furthermore, researchers will focus on detailing the exact molecular and cellular mechanisms by which CHIP is functionally implicated in the development and progression of aggressive cancers. This will involve further exploration of signalling pathways, cellular interactions, and the precise genetic and epigenetic changes induced by TI-CH.
In conclusion, this international collaboration has not only identified a potent new prognostic factor in cancer but has also unlocked a critical new understanding of how ageing fundamentally shapes the cancer landscape. The journey from observing age-related mutations to demonstrating their active role in tumour aggression represents a monumental leap forward, holding immense promise for revolutionizing cancer diagnosis, treatment, and potentially, even prevention in the years to come.
About the Author
